CA1041491A - Process for the manufacture of new amines - Google Patents
Process for the manufacture of new aminesInfo
- Publication number
- CA1041491A CA1041491A CA187,308A CA187308A CA1041491A CA 1041491 A CA1041491 A CA 1041491A CA 187308 A CA187308 A CA 187308A CA 1041491 A CA1041491 A CA 1041491A
- Authority
- CA
- Canada
- Prior art keywords
- process according
- formula
- hydroxyl
- split
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 150000001412 amines Chemical class 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 9
- JZEHWMUIAKALDN-UHFFFAOYSA-N 1-amino-3-phenoxypropan-2-ol Chemical class NCC(O)COC1=CC=CC=C1 JZEHWMUIAKALDN-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 54
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 46
- -1 1-methyl-3-phenyl-propyl Chemical group 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 239000004593 Epoxy Substances 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229960005419 nitrogen Drugs 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 5
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 4
- 238000003797 solvolysis reaction Methods 0.000 claims description 4
- 150000004678 hydrides Chemical class 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000958 aryl methylene group Chemical group 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 229910052987 metal hydride Inorganic materials 0.000 claims 1
- 150000004681 metal hydrides Chemical class 0.000 claims 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical class [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 4
- 239000004041 inotropic agent Substances 0.000 abstract description 2
- 210000004165 myocardium Anatomy 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 description 17
- 239000002253 acid Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229910052783 alkali metal Inorganic materials 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 150000001340 alkali metals Chemical class 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GZCPWFOPXIDRDP-UHFFFAOYSA-N 3-(propan-2-ylamino)propan-1-ol Chemical compound CC(C)NCCCO GZCPWFOPXIDRDP-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical class NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000006307 alkoxy benzyl group Chemical group 0.000 description 2
- 125000006177 alkyl benzyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000006178 methyl benzyl group Chemical group 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940031826 phenolate Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- RNFDZDMIFOFNMC-UHFFFAOYSA-N 1-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NCC(C)O RNFDZDMIFOFNMC-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- 125000004797 2,2,2-trichloroethoxy group Chemical group ClC(CO*)(Cl)Cl 0.000 description 1
- LNSCNEJNLACZPA-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(2-methylphenyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(O)(C(O)=O)C(O)(C(O)=O)C1=CC=CC=C1C LNSCNEJNLACZPA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910021554 Chromium(II) chloride Inorganic materials 0.000 description 1
- 102100032392 Circadian-associated transcriptional repressor Human genes 0.000 description 1
- 101710130150 Circadian-associated transcriptional repressor Proteins 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910001297 Zn alloy Inorganic materials 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- WDNIVTZNAPEMHF-UHFFFAOYSA-N acetic acid;chromium Chemical compound [Cr].CC(O)=O.CC(O)=O WDNIVTZNAPEMHF-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- UZEDIBTVIIJELN-UHFFFAOYSA-N chromium(2+) Chemical class [Cr+2] UZEDIBTVIIJELN-UHFFFAOYSA-N 0.000 description 1
- XBWRJSSJWDOUSJ-UHFFFAOYSA-L chromium(ii) chloride Chemical compound Cl[Cr]Cl XBWRJSSJWDOUSJ-UHFFFAOYSA-L 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- VLSTXUUYLIALPB-UHFFFAOYSA-N n-propan-2-ylpropan-1-amine Chemical compound CCCNC(C)C VLSTXUUYLIALPB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002447 thiram Drugs 0.000 description 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Process for the manufacture of new amines Abstract of the Disclosure 1-Phenoxy-2-hydroxy-3-amino-propanes of the formula I
Description
~o~
The invention relates to new l-phenoxy-2 hydroxy-3-amino-propanes of the formula I
Rl-0 _ - ~ -CH2cHHcH2-NH-R2 wherein Rl is a l-glucop~ranosidyl residue and R2 is isopropyl, tert -butyl or ~-methyl-phenethyl or l-methyl-3-phenyl-propyl which are optionally sub-stituted in the phenyl part, and to processes for their manufacture The compounds of formula I can be made by a process wherein a) a phenol of the formula II
- , .
Rl-0 __ ~ OH ~II) lQ wherein Rl has the above meaning, is reacted with a compound of the formula III X
Il :: .: .
Z - CH2 - CH - CH2 - NH R2 ~III) ; i! ;
wherein R2 has the above meaning, Z is reactive esterified hydroxyl and Xl is hydroxyl or Z and Xl together are epoxy, or Z and thè hydrogen of the amino ~. , ~ ...
group together are a direct bond, or b) a compound o~ the formula IV
,. , X .: .:
l- ~ 0-CH2-CH-CH2 Zl ~IV) ;
wherein Rl has the above meaning is reacted with a compound of the formula V
The invention relates to new l-phenoxy-2 hydroxy-3-amino-propanes of the formula I
Rl-0 _ - ~ -CH2cHHcH2-NH-R2 wherein Rl is a l-glucop~ranosidyl residue and R2 is isopropyl, tert -butyl or ~-methyl-phenethyl or l-methyl-3-phenyl-propyl which are optionally sub-stituted in the phenyl part, and to processes for their manufacture The compounds of formula I can be made by a process wherein a) a phenol of the formula II
- , .
Rl-0 __ ~ OH ~II) lQ wherein Rl has the above meaning, is reacted with a compound of the formula III X
Il :: .: .
Z - CH2 - CH - CH2 - NH R2 ~III) ; i! ;
wherein R2 has the above meaning, Z is reactive esterified hydroxyl and Xl is hydroxyl or Z and Xl together are epoxy, or Z and thè hydrogen of the amino ~. , ~ ...
group together are a direct bond, or b) a compound o~ the formula IV
,. , X .: .:
l- ~ 0-CH2-CH-CH2 Zl ~IV) ;
wherein Rl has the above meaning is reacted with a compound of the formula V
2 R2 tv) ~: .
;wherein R2 has the above meaning, one of the radicals Zl and Z2 is aminQ and thé~other l~ reactiv. esterlfied hydroxyl and Xl is hydroxyl~, or Zl together with Xl are epoxy and Z2 is amino, or c) in a compound of the formula I, except that the compound -carries a radical which can be split off on the amino group and/or on the hy- -droxyl group, this~radical or these radicals is or are split off, d) a compound corl~esponding to the formula I, wherein the nitro-gen is doubly bonded to one of its substituents, or wherein a C atom bonded to the nitrogen carries a hydroxyl group~ is reduced, or /': ,: .
49~
e) a compound of formula I in which Rl contains one or more protective groups is subjected to solvolysis or hydrogenolysis to remove the protective group or groups, and if desired, resulting racemate mixtures are separated into the pure racemates and/or resulting racemates are separated into the optical antipodes and/or resulting salts are converted into other pharmaceutically acceptable salts or into the free compounds or resulting free compounds are converted into their pharmaceutically acceptable salts.
The l-glucopyranosidyI residue can contain protective groups on the hydroxyl groups.
As protective groups there are in particular to be understood those substituted hydroxyl groups which can be converted into free hydroxyl ~ -groups, for example as described below.
Subs~ituted hydroxyl groups are, in particular, etherified or esterified hydroxyl groups.
Etherified hydroxyl groups are, for example, aliphatically or araliphatlcally etheri~ied hydroxyl, such as lower alkoxy~ for example those with up to 7 and in particular with up to 4 C atoms, such as ethoxy and es- ~
pecially methoxy or n-propoxy, or phenyl-lower alkoxy optionally substituted ` -in the phenyl part, wherein the ~:
~;~
'' c: ~ :
~ _ 2a -B~ :~
; .:
`` 1~41~
lower alkoxy part in particular corresponds to the ahove lower alkoxy and is preferably methyleneoxy and wherein examples of substituents which may be mentioned are lower alkyl such as lower alkyl wi.th up to 7, in particular with up to 49 C atoms, such as i- or n-propyl, ethyl or especially methyl, lower alkoxy, such as mentioned above9 .;:~
trifluoromethyl and especially halogen, such as bromine and ;.
above all chlorine, as well as lower alkylbenzyl, for example methylbenzyl, lower alkoxybenzyl, for example methoxybenzyl, trifluoromethylbenzyl or in particular ~
benzyl or halogenobenzyl, for example chlorobenzyl. ~ `-.: :; . `
Etherified hydroxyl groups, for example also .; .
include those in which two adJacent or sterically adjacent hydroxyl groups are together replaced by an ylidenedioxy . ;
radical. Ylidenedioxy is, in particular, lower alkylidene- ::
dioxy, such as lower alkylidenedioxy with up to 7, above . .;;
all with up to 4 C atoms, such as, in particular,~iso~
propylidenedioxy or optionally substituted:benzylidenedloxy, ~:
such as benzylidenedioxy substituted by lower.alkyl, .... ..
lower alkoxy or halogen, for example methylbenzylidene-dioxy, methoxybenzylidenedioxy or chlorobenzylidenedioxy ~ ~.
and especially benzylidenedioxy. .~
. . .
. ~ Esterified hydroxyl groups are, for ex~nple~ lower : aIkanoyloxy, for example with up to 7, especially with up ~, . .. .
: to:4~,~C atoms~ such as propionyloxy or especially acetoxy, or~optionally~:substltuted~benzo~loxy, wherein examples of ~ ; i : `substi-tuents which may~be mentioned are lower alkyl, such ..
as~mentioned above:, lower alkoxy, such as mentioned above, : . . . . . .
~ 14~
or halogen, such as mentioned above, such as methylbenzoyl 9 methoxybenzoyl, chlorobenzoyl or especially benzoyl.
~ -Methylphenethyl or l-methyl-3--phenyl-propyl R2 optionally substituted in the phenyl part is, for example, a-methylphenethyl or l-methyl~3-phenyl-propy substituted in the phenyl par-t by hydroxyl or lower alkoxy. Lower alkoxy is therein in particular lower alkoxy with up to 7 C a-toms9 above all with up to 4 C atoms, such as ethoxy, n- or iso-propoxy, n-, sec.- or tert.-butoxy or above all methoxy~ m us, a-methyl-phenethyl optionally substituted .
in the phenyl part is, for example, o-, m- or p-hydroxy~
methyl-phenethyl, o-, m- or p-methoxy-a-methyl-phenethyl and above all a-methylphenethyl unsubs-tituted in -the phenyl part. Equally, l-methyl-~-phenyl-propyl optionally sub-stituted in the phenyl part is, for exa~ple 1-methyl-3-phenyl-propyl substituted in the phenyl part by hydroxyl ~-br methoxy in the o-, m- or p-position, and above all l-methyl-3-phenyl-propyl unsubstituted in the phenyl part.
i.. ; , .
~ The new compounds possess advantageous pharmaco-.
logical properties. Thus they show a positively chrono~
tropic and in particular a positively inotropic action, as can above all be demonstrated by an increase in the myo-cardiac contractibility (probably due to direct stim~a-tion o~ the ~-receptors~ and of the pulse rate9 for -example as can be demonstrated on~non-narcotised dogs by recording various contractibility parameters, such as maxi-mum acceleration of the blood ~low m the aorta and of the pulse~rate on oral a~ministration in doses of about 0.1 to ~ 4 ~ ~
,;
- . . . . ... .
:~L()41491 ::
abou-t 10 mg/kg. The new compounds can therefore be used as positively inotropic agents, especially in the treat- -ment of insufficiency of the cardiac muscle.
,, ! ' They can furthermore also be used as valuable intermediate products for the manufacture of other useful substances, especially of pharmaceutically active compounds. ` -Compounds to be singled out are l-phenoxy 2-hydroxy-
;wherein R2 has the above meaning, one of the radicals Zl and Z2 is aminQ and thé~other l~ reactiv. esterlfied hydroxyl and Xl is hydroxyl~, or Zl together with Xl are epoxy and Z2 is amino, or c) in a compound of the formula I, except that the compound -carries a radical which can be split off on the amino group and/or on the hy- -droxyl group, this~radical or these radicals is or are split off, d) a compound corl~esponding to the formula I, wherein the nitro-gen is doubly bonded to one of its substituents, or wherein a C atom bonded to the nitrogen carries a hydroxyl group~ is reduced, or /': ,: .
49~
e) a compound of formula I in which Rl contains one or more protective groups is subjected to solvolysis or hydrogenolysis to remove the protective group or groups, and if desired, resulting racemate mixtures are separated into the pure racemates and/or resulting racemates are separated into the optical antipodes and/or resulting salts are converted into other pharmaceutically acceptable salts or into the free compounds or resulting free compounds are converted into their pharmaceutically acceptable salts.
The l-glucopyranosidyI residue can contain protective groups on the hydroxyl groups.
As protective groups there are in particular to be understood those substituted hydroxyl groups which can be converted into free hydroxyl ~ -groups, for example as described below.
Subs~ituted hydroxyl groups are, in particular, etherified or esterified hydroxyl groups.
Etherified hydroxyl groups are, for example, aliphatically or araliphatlcally etheri~ied hydroxyl, such as lower alkoxy~ for example those with up to 7 and in particular with up to 4 C atoms, such as ethoxy and es- ~
pecially methoxy or n-propoxy, or phenyl-lower alkoxy optionally substituted ` -in the phenyl part, wherein the ~:
~;~
'' c: ~ :
~ _ 2a -B~ :~
; .:
`` 1~41~
lower alkoxy part in particular corresponds to the ahove lower alkoxy and is preferably methyleneoxy and wherein examples of substituents which may be mentioned are lower alkyl such as lower alkyl wi.th up to 7, in particular with up to 49 C atoms, such as i- or n-propyl, ethyl or especially methyl, lower alkoxy, such as mentioned above9 .;:~
trifluoromethyl and especially halogen, such as bromine and ;.
above all chlorine, as well as lower alkylbenzyl, for example methylbenzyl, lower alkoxybenzyl, for example methoxybenzyl, trifluoromethylbenzyl or in particular ~
benzyl or halogenobenzyl, for example chlorobenzyl. ~ `-.: :; . `
Etherified hydroxyl groups, for example also .; .
include those in which two adJacent or sterically adjacent hydroxyl groups are together replaced by an ylidenedioxy . ;
radical. Ylidenedioxy is, in particular, lower alkylidene- ::
dioxy, such as lower alkylidenedioxy with up to 7, above . .;;
all with up to 4 C atoms, such as, in particular,~iso~
propylidenedioxy or optionally substituted:benzylidenedloxy, ~:
such as benzylidenedioxy substituted by lower.alkyl, .... ..
lower alkoxy or halogen, for example methylbenzylidene-dioxy, methoxybenzylidenedioxy or chlorobenzylidenedioxy ~ ~.
and especially benzylidenedioxy. .~
. . .
. ~ Esterified hydroxyl groups are, for ex~nple~ lower : aIkanoyloxy, for example with up to 7, especially with up ~, . .. .
: to:4~,~C atoms~ such as propionyloxy or especially acetoxy, or~optionally~:substltuted~benzo~loxy, wherein examples of ~ ; i : `substi-tuents which may~be mentioned are lower alkyl, such ..
as~mentioned above:, lower alkoxy, such as mentioned above, : . . . . . .
~ 14~
or halogen, such as mentioned above, such as methylbenzoyl 9 methoxybenzoyl, chlorobenzoyl or especially benzoyl.
~ -Methylphenethyl or l-methyl-3--phenyl-propyl R2 optionally substituted in the phenyl part is, for example, a-methylphenethyl or l-methyl~3-phenyl-propy substituted in the phenyl par-t by hydroxyl or lower alkoxy. Lower alkoxy is therein in particular lower alkoxy with up to 7 C a-toms9 above all with up to 4 C atoms, such as ethoxy, n- or iso-propoxy, n-, sec.- or tert.-butoxy or above all methoxy~ m us, a-methyl-phenethyl optionally substituted .
in the phenyl part is, for example, o-, m- or p-hydroxy~
methyl-phenethyl, o-, m- or p-methoxy-a-methyl-phenethyl and above all a-methylphenethyl unsubs-tituted in -the phenyl part. Equally, l-methyl-~-phenyl-propyl optionally sub-stituted in the phenyl part is, for exa~ple 1-methyl-3-phenyl-propyl substituted in the phenyl part by hydroxyl ~-br methoxy in the o-, m- or p-position, and above all l-methyl-3-phenyl-propyl unsubstituted in the phenyl part.
i.. ; , .
~ The new compounds possess advantageous pharmaco-.
logical properties. Thus they show a positively chrono~
tropic and in particular a positively inotropic action, as can above all be demonstrated by an increase in the myo-cardiac contractibility (probably due to direct stim~a-tion o~ the ~-receptors~ and of the pulse rate9 for -example as can be demonstrated on~non-narcotised dogs by recording various contractibility parameters, such as maxi-mum acceleration of the blood ~low m the aorta and of the pulse~rate on oral a~ministration in doses of about 0.1 to ~ 4 ~ ~
,;
- . . . . ... .
:~L()41491 ::
abou-t 10 mg/kg. The new compounds can therefore be used as positively inotropic agents, especially in the treat- -ment of insufficiency of the cardiac muscle.
,, ! ' They can furthermore also be used as valuable intermediate products for the manufacture of other useful substances, especially of pharmaceutically active compounds. ` -Compounds to be singled out are l-phenoxy 2-hydroxy-
3-amino-propanes Ia o~ the formula I, wherein R1 is optionally O-lower alkylated, O-aryl-lower alkylated, O-lower alkanoylated, O-benzoylated or O,O-ylideneylated l-glucopyranosidyl and R2 is isopropyl, tert.-butyl or . .
a-methylphenethyl or l-methyl-3-phenyl-propyl which are optionally substituted in the phenyl part.
. .
Compounds to be particularly singled ou-t are , .. . ...
l-phenoxy-2-hydroxy-3-amino-propanes Ib of the formula I, wherein Rl is O-me-thyl-l-glucopyranosidyl, O-benzyl-l-gluco-pyranosidyl, O-chlorobenzyl-l-glucopyranosidyl, O-acetyl-l- `
glucopyranosidyl, O-benzoyl-l-glucopyranosidyl, 2,4-0-iso-propylidene-l-glucopyrànosidyl, Z,4-0-benzylidene-1-gluco-pyranosidyl or l-glucopyranosidyl and R2 is isopropyl, .
tert.-butyl or ~-methylphenethyl or l-methyl-3-phenyl-propyl which are optionally substituted in -the phenyl part by hydroxyl or lower alkoxy.
~-Above all there should be mentioned l-phenoxy-2- ` -;
hydroxy-3-amino-propanes Ic of the ~ormula I, wherein Rl i9 ~ ~
glucopyranosidyl and R2 is isopropyl or tert.-butyl. ~ -Compounds to be singled out by name are in particu lar l-[p~ D-glucopyranosidyloxy)--phenoxy~-2-hydroxy~3- -,, ~ . .
. . , . . I .
: .: : . .; .
~ L~4~19~
isopropylamino~propane and the compounds named in the examples.
m e new l-phenoxy-2-hydroxy-3-amino-propanes can be manufactured according to methods which are in them-sel~es known.
It is possible to react a phenol of the formula II
Rl - O ~ OH . (II) -wherein Rl has the above meaning, with a compound of the formula III
Z - CH2 - CH - CH2 - NH - R2 . ~III) wherein R2 has the above meaning, Z is reac-tive esteri-fied hydroxy]. and Xl is hydroxyl or Z and Xl together are epoxy, o~ Z and the hydrogen of the amino group together are a direct bond.
Reactive esterified hydroxyl is, in particular a hydroxyl group esterified hy strong inorganic or organic .
acids~ above all a ~ogen halide acid, such as hydro-chloric acid9 hydrobromic acid or hydriodic acid, also sulphuric acid or an organic sulphonic acid, such as an aromatic sulphonic acid, ~or example benzenesulphonic acid, 4-bromobenzenesulphonic acid or 4-toluenesulphonic acid. ~:Thus, reactive esterifled hydroxyl in partlcular represents chlorine, bromine or iodine~ ~
: mis reaction can be carried out in the customary - :
~ ~ ,~ . .. . .. .
~ manner. If reactive esters are used as starting mater~als : , ~ : , .
... .
!.`. .
a-methylphenethyl or l-methyl-3-phenyl-propyl which are optionally substituted in the phenyl part.
. .
Compounds to be particularly singled ou-t are , .. . ...
l-phenoxy-2-hydroxy-3-amino-propanes Ib of the formula I, wherein Rl is O-me-thyl-l-glucopyranosidyl, O-benzyl-l-gluco-pyranosidyl, O-chlorobenzyl-l-glucopyranosidyl, O-acetyl-l- `
glucopyranosidyl, O-benzoyl-l-glucopyranosidyl, 2,4-0-iso-propylidene-l-glucopyrànosidyl, Z,4-0-benzylidene-1-gluco-pyranosidyl or l-glucopyranosidyl and R2 is isopropyl, .
tert.-butyl or ~-methylphenethyl or l-methyl-3-phenyl-propyl which are optionally substituted in -the phenyl part by hydroxyl or lower alkoxy.
~-Above all there should be mentioned l-phenoxy-2- ` -;
hydroxy-3-amino-propanes Ic of the ~ormula I, wherein Rl i9 ~ ~
glucopyranosidyl and R2 is isopropyl or tert.-butyl. ~ -Compounds to be singled out by name are in particu lar l-[p~ D-glucopyranosidyloxy)--phenoxy~-2-hydroxy~3- -,, ~ . .
. . , . . I .
: .: : . .; .
~ L~4~19~
isopropylamino~propane and the compounds named in the examples.
m e new l-phenoxy-2-hydroxy-3-amino-propanes can be manufactured according to methods which are in them-sel~es known.
It is possible to react a phenol of the formula II
Rl - O ~ OH . (II) -wherein Rl has the above meaning, with a compound of the formula III
Z - CH2 - CH - CH2 - NH - R2 . ~III) wherein R2 has the above meaning, Z is reac-tive esteri-fied hydroxy]. and Xl is hydroxyl or Z and Xl together are epoxy, o~ Z and the hydrogen of the amino group together are a direct bond.
Reactive esterified hydroxyl is, in particular a hydroxyl group esterified hy strong inorganic or organic .
acids~ above all a ~ogen halide acid, such as hydro-chloric acid9 hydrobromic acid or hydriodic acid, also sulphuric acid or an organic sulphonic acid, such as an aromatic sulphonic acid, ~or example benzenesulphonic acid, 4-bromobenzenesulphonic acid or 4-toluenesulphonic acid. ~:Thus, reactive esterifled hydroxyl in partlcular represents chlorine, bromine or iodine~ ~
: mis reaction can be carried out in the customary - :
~ ~ ,~ . .. . .. .
~ manner. If reactive esters are used as starting mater~als : , ~ : , .
... .
!.`. .
4~
o~ the formula III or compounds of the formula III wherein Z and the hydrogen o~ the amino group together form a direct bond, a co~pound of the formula II can advantage- ~:
ously be used in the form of its metal phenolate, such as : :
alkali metal phenolate, for example sodium phenolate, or the reaction is carried out in the presence of an acid-binding agent, especially of a condensation agent, ~hich can form a salt with a compound of the formula II, such as :.
in the presence of an alkali me-tal alcoholate, ~or example `
an alkali metal lower alkanolate, such as sodium me-thylate ~.:
or sodium ethylate.
It is furthermore possible~ for example, to react a compound o~ the formula IV
- . . ;,~, .. ,~ ,." .
... . ...
. 11 (IV) R~3~CH2--a~aX~ Zl ;
wherein Rl has the above meaning, with a compound of ~-the~
formula V ~ ~ -Z2 ~ R2 (V) wherein R2 h~s the above meaning, one of the radicals Zl :
and Z2 is amino and the other is reactive esterified hydroxyl and Xl is hydroxyl, or Zl toge-ther with Xl is ;:
epoxy and Z2 is amino.
Reactive esterified hydroxyl is, in partlcular,:a hydroxyl group esterified by a strong inorganic or organic aoid~ above all a hydrogen halîde acl~, such as hydro~
chloric acid~ hydrobromic acid or hydriodic acid, or :
_ 7 ~
~,1 : ' ~ : ' , ~ ...
~ \
~04~L49~ -sulphuric acid or an organic sulphonic acid, such as an aromatic sulphonic acid, for example benzenesulphonic acid, 4-bromobenzenesulphonic acid or 4-toluenesulphonic acid~
Thus, reactive esterified hydroxyl is, in particular, chlorine, bromine or iodine.
This reaction can be carried out in the usual manner. If a reactive ester of the formula IV or V is used, the reaction is preferably carried out in the pre-sence of a basic condensation agent and/or with an excess o~ amine of the formula IV. Examples of suitable basic condensation agents are alkali metal hydroxides, such as sodium hydroxide or potassium hydroxide~ alkali metal ;
carbonates, such as potassium carbonate, and alkali metal ;~
alcoholates, such as alkali metal lower alkanolates, for example sodium methylate, po-tassium ethylate or potassium . ~ , .. .
ter-tiary butylate. ~ -;
Furthermore it is possible, in a compound of the formula I, wherein Rl and R2 have the above meanings and which possess~a removable radical~on the amino group and/or on the hydroxyl group, to spllt off this radical or these radicals. ~-Such radicals which can be spli-t off are in particu-lar radicals which can be split off by solvolysis or by reduotion. ~
Examples of radloals which can be split off by ;reduction are a-arylalkyl radicals, such as benzyl radi- ~-cals,~ and ~-aralkoxycarbonyl radicals, such as benzyloxy-carbonyl rsdic~1-, whloh can~be s 1lt off in the usua1 . .
~ 4~L~9~
manner by hydrogenol~sis, especially by catalytically activated hydrogen, such as by hydrogen in the presence of a hydrogenation catalyst, for example platinum, palladium or Raney nickel. Further radicals which can be split off by hydrogenolysis are, for example, 2-halogenoalkoxy-carbonyl radicals~ such as the 2,2,2-trichloroethoxy~ - -carbonyl radical or the 2-iodoethoxy-carbonyl or Z,2,2-tribromoethoxy-carbonyl radical, which can be split off in ... ~ .. .. .
the customary manner9 especially by metallic reduction (so-called nascent hydrogen). Nascent hydrogen can be ;
obtained by the action of metal or metal alloys, such as amalgams, on agents which provide hydrogen, such as weak carboxylic acids, alcohols or water, and in particular zinc or zinc alloys together with ethanol or dilute aqueous acetic acid can be used. The hydrogenolysis of 2-halogeno-alkoxycarbonyl radicals can furthermore be effec-ted by chromium-(II) compounds, such as chromium-(II) chloride or chromium-(II) acetate. A radical which can be split off by reduction can also be an arylsulphonyl group,~such as the toluenesulphonyl group, which can be : :... .
split off in the customary manner by reduction with nascent hydrogen, for example by means of an alkali metal, : ~ .
such as lithium or sodium, in liquid ammonia, and can in ~; particular be split off from a N a-tom. :
Divalent radicals which can be split of~ by reduc- -tion~and which are substituents of the hydroxyl group and the~amlno group are, ~or example, optionally substitu-ted ;~
methylene radicals9~such as arylmethylene radicals, such -~04~ ~9~ ~
as optionally substituted benzylidene radicals, possikle substituents on the phenyl nucleus being, ~or example, halogen, such as chlorine, lower alkyl such as m~thyl, or lower alkoxy, such as methoxy. Thus, arylmethylene is in particular benzylidene. The splitting off can be effected in the customary manner, for example by catalytic ally activated hydrogen, such as by hydrogen in the pre-sence of a hydrogenation catalyst, for example platinum9 palladium or Raney nickel.
A further possible procedure is to reduce a com-pound corresponding to the formula I, wherein the nitrogen is doubly bonded to one of its substituents, or wherein a C atom bonded to the nitrogen carries a hydroxyl group.
Thus, for example, a possible procedure is -to :
. ,:. . . .
reduce a Schiff's base of the formula VI or VII
., - .
- ~ ~1 ~ O-CH2CHOHCH~-N=R2 (VI) `
~: : ~ - . ' ,". :; ., .
~ 1 ~ 0-CH2CHOECH=~ R2 (VII) ~ ~
. . -: .
or a ring tautomer corresponding to the ~ormula VI, of the ~ ~
.,; : , ~ormula VIII - -~
--- . , .
R - ~ ~CU2~ 2 (VIII) wherein Rl and R2 have the~above meaning and~R2H is ;~
:: : : : ` ' ', : ., : ` ' ~ : `: : . ' .: : "
~(~4~9~9~ `:
identical to R2.
mis reduc-tion can be effec-ted in the customary manner, for example by means of a di-light me-tal hydride, such as an alkali metal borohydride or alkali metal aluminium-hydride, for example lithium aluminium hydride, by means of a hydride, such as diborane~ or by means of hydrogen in the presence of a hydrogenation catalyst, for example platinum~ palladium or nickel, such as Raney nickel.
Care must be taken in carrying out the reduction that ~other reducible groups are not attacked.
In resulting compounds it is possible, within the ;
definition of the end products, to modify, introduce or split off substituents in the usual manner; alternatively, resulting compounds can be converted into other end pro- `~
ducts in the customary manner.
Thus it is possible to split off the protective ~`
groups in resulting compounds which carry protective groups in the sugar residue Rl. For example it is pos- ~ ~
sible, in resulting compounds in which one or more hydroxyl `
groups in the sugar residue are protected by an optionally `
substituted benzyl radical or in which two adjacen-t hyd--..... : , roxyl groups in the sugar residue Rl are together pro-tected .. . ;
by an optionally substituted benzylidene radical, to split off these radicals in the usual manner. Optionally ; . . .
substituted benzyl is, for~example, halogenobenzyl, such ~-as~chlorobenzyl,~lower alkylbenzyl, such as methylbenzyl ~;
or lower alkoxybenzyl, such as ~ethoxybenzyl, and in parti- ;
cul~r unsubstitu-ted benzyl. Optionally substituted ~
` ~ :
~:
~ , .
, ~ 4 ~ ~9 ~ :
benæylidene is, for example, halogenobenzylidene, such as chlorobenzylidene, lower alkylbenzylidene, such as methyl- ~
benzylidene, or lo-.le.r alkox~benzylidene such as methoxy- -benzylidene, and especially unsubstituted benzylldene.
m e splitting off can for example be effected by reduction, for example by treatment with catalytically activated hydrogen, such as hydrogen in -the presence of a hydro-genation catalyst, ~or example platinum, palladium or Raney nickel, yielding corresponding compounds with free : `
hydroxyl groups in the sugar residue Rl. :~
In resulting compounds in which one or more hydroxyl groups in the sugar residue Rl are protected by acyl, the acyl radicals can be split off in the customary ; .
manner, for example by hydrolysis or by alcoholysiæ, .~.`
preferably in the presence of a m.ild basic agent, such as -. ..
an alkali metal bicarbonate, for example sodium bicar~
bonate, giving corresponding compounds with free hydroxyl ~:
groups in the sugar residue R~
The reac-tions mentioned can op-tionally be carried i :
out simultaneously or successively and in optional sequence.
; me reactions mentioned are carried out in the : `~
usual manner in the presence or absence of : ~diluents, condensation agents and/or cataly-tic agents~ at ; .
: : lowered, ordinary or elevated temperature and if approp~
riate:in a closed vessel~
Depending on -the process conditions and starting aubstances, the end products are obta~ned in the free form or in the form o~ their acid addition salts, ~hich is also ~, . . . ..
.
encompassed by ~he inven-tion. Thus, for example, ~`
basic, neutral or mixed salts and where relevant also hemihydrates, monohydrates, sesquihydrates or poly-hydrates thereof7 can be obtained. The acid addition sal-ts o~ the new compounds can be converted into the free compo~md in a manner which is in itself known, for example by means of basic agents, such as alkalis or ion exchangers.
On -the other hand, the resulting ~ree bases can form salts with organic or inorganic acids. Acids used for the preparation of acid addition salts are in particular those which are suitable for forming therapeutically usable salts. ~ -As examples of such acids there may be mentioned, hydrogen halide acids, sulphuric acids, phosphoric acids, nitric `~ ~ ;
acid and aliphatic, alicyclic, aromatic or heterocyclic carboxylic acids or sulphonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid or pyruvic acid, fumaric acid, benzoic acid, anthranilic acid, p-hydroxybenzoic acid~
salicylic acid or embonic acid, methanesulphonic acid, ethanesulphonic acid, hydroxyethanesulphonic acid or ethylenesulphonic acid, halogenobenæenesulphonic acids, toluenesulphonic acid~ cyclohexylaminesulphonic acid or sulphanilic acid.
; These~or other salts of the new compounds such as, for example7 the picrates~ can also serve for the puri fication of ~he resul-ting ~ree bases by converting the ;
~ree~bases into salts, and isolating these and again i , ~ ~ .:. , .
:
: : . , , l - 13 - ; ~
~: ~ : ,.
3L~)4~
liberating the bases from the salts. Because of the close relationships between the new compounds in the free form and in the form of their salts, the free compounds are, in the preceding and following text, where appropriate also to be understood to include the corresponding salts, with regard to general sense and intended use.
m e invention also relates to those embodiments of .
the process according to which a compound obtainable as an intermediate product at any stage of -the process is used as ~he starting product and the missing process steps are carried ou-t, or the process is stopped at any sta~e, or in which a starting substance is formed under the reaction .
conditions or in which a reactant is presen-t in the form of its salts, if appropriate.
For e~ample, a possible procedure is to react an -aldehyde o~ the formula IX
~ ~ O-CH2CHO~-CHO (IX) -~
,.
with an amine H2N-R2 in the presence of a reducing agent, -- Rl and R2 having the above meaning. mis gives a compound of the formula VII as an intermediate product, which is then reduced further in accordance with the inventionO
However, another possible procedure is, for example, to` react an amine of the formula X ~
R~- ~ o-oH2cHoHc~I2-~I2 (X) ~: - . ~ . . .. .
~0~49:~
with a ketone O=R2 in the presence of a reducing agent, such as one of those mentioned above9 R2H being equivalent to R2 and Rl and ~2 having the above meaning. This gives a compound of the formula VI or VIII as an intermediate product which is then reduced further in accordance with the invention. In this case it is also possible to form i the amine X in situ, for example from one of its Schiff's bases with an optionally substituted benzaldehyde, which base is converted in situ, in particular by means of catalytic hydrogenation, into the amine X, which then --reacts further in accordance with the invention.
The new compounds can, depending on the choice of the starting substances and procedures, be in -the form of optieal antipodes or racemates or, where -they contain at least two asymmetrical carbon atoms, also in the form of isomer mixtures.
Resulting isomer mixtures ean be separated into the two stereoisomeric (diastereomeric) pure racemates ln a known manner on the basis of the physico-ehemical differences o~ the cons-tituen-ts, for example by chromato- i graphy and/or fractional crys-talllsation. i~
Resulting racemates can be resolved in-to the diastereomers according to known methods, for example by recrystallisation from an op-tically ac-tive solvent, with i ~ ....................................................................... .
the~aid of micro-organlsms or by reaction with an optically -;
aotive acid which forms sal-ts with the racemic compound and separation o~ the salts obtained in this manner, ~or example on the basis of thelr dlfferent solubillties, and ~ ; ;~
~. ..
;. : ., .. . .
, ~,.: , ~4~4~
the antipodes can be liberated from the diastereomers by ~ -treatment with suitable agen-ts. Par-ticularly cus-tomary optically ac-tive aGids are, for example, the D- and L- ~ -forms of tartaric acid, di-o-toluyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid or quinic acidO
Advantageously, the more active of the two antipodes is isolated.
Preferably, the starting substances used for carrying out the reactions according to the invention are -those which lead to the groups of end products which were particularly mentioned initially and especially to the end ~ -products which have been particularly described or singled out.
m e starting substances are known or can, i~ they `
are new, be obtainecl according to methods which are in -themselves known. Compounds IV can be prepared in the usual manner from a phenol II by reaction with a reactive ;~
derivative o~ a propanol HOCH2-CHXl-CH2Zl, such as, for example, with epichlorohydrin. Compounds I with removable ;
radicals on the amino group and/or hydroxyl group can be -:~ : ~ ..... : :
manufactured analogously to the compounds IV, as can compounds VI-X.
The new compounds can be used as medicines, for ~ ;`
example in the ~orm of pharmaceutical preparations in ~`
which they or their salts are present as a m1xture with a~pharmaceu-tical,~ organic or inorgan1c9 solid or Iiquid excip1ent~wh1ch~is su1table ~or,~ for example, enteral or-parenteral administration~ Suitable substances for 3~4~L491 ~ :
forming the excipient are those which do not react wi-th ;
the new compounds such as, for example~ water, gelatine, lactose, starch, magnesium s-teara-te, talc7 vegetable oils, benzyl alcohols, polyalkylene glycols or o-ther known medicinal excipients. The pharmaceutical preparations can for example be in the form of tablets7 dragees, capsules or suppositories or in a liquid form as solu-tions -(for example as an elixir or syrup), suspensions or emulsions. m ey are optionally sterilised and/or contain auxiliaries, such as preservati~es, stabilisers, wetting agents or emulsifiers, salts for regulating the osmotic pressure or buffers. The preparations, which can also be used in veterinary medicine, are obtained according to customary me-thods. The daily dose for a warm-blooded animal o~ about 75 kg body weigh-t is about 10-100 mg, preferably about 20-40 mg.
me examples which follow explain the invention wlthout however restricting it. ;
Example 1 -i6.4 g (0.05 mol) of 4-(2,3-epoxy-propoxy?-phenyl~
~-D-glucopyranoside and 11.8 g (0.20 mol) of isopropyl-amine are dissolved in 250 ml of methanoI and heated for
o~ the formula III or compounds of the formula III wherein Z and the hydrogen o~ the amino group together form a direct bond, a co~pound of the formula II can advantage- ~:
ously be used in the form of its metal phenolate, such as : :
alkali metal phenolate, for example sodium phenolate, or the reaction is carried out in the presence of an acid-binding agent, especially of a condensation agent, ~hich can form a salt with a compound of the formula II, such as :.
in the presence of an alkali me-tal alcoholate, ~or example `
an alkali metal lower alkanolate, such as sodium me-thylate ~.:
or sodium ethylate.
It is furthermore possible~ for example, to react a compound o~ the formula IV
- . . ;,~, .. ,~ ,." .
... . ...
. 11 (IV) R~3~CH2--a~aX~ Zl ;
wherein Rl has the above meaning, with a compound of ~-the~
formula V ~ ~ -Z2 ~ R2 (V) wherein R2 h~s the above meaning, one of the radicals Zl :
and Z2 is amino and the other is reactive esterified hydroxyl and Xl is hydroxyl, or Zl toge-ther with Xl is ;:
epoxy and Z2 is amino.
Reactive esterified hydroxyl is, in partlcular,:a hydroxyl group esterified by a strong inorganic or organic aoid~ above all a hydrogen halîde acl~, such as hydro~
chloric acid~ hydrobromic acid or hydriodic acid, or :
_ 7 ~
~,1 : ' ~ : ' , ~ ...
~ \
~04~L49~ -sulphuric acid or an organic sulphonic acid, such as an aromatic sulphonic acid, for example benzenesulphonic acid, 4-bromobenzenesulphonic acid or 4-toluenesulphonic acid~
Thus, reactive esterified hydroxyl is, in particular, chlorine, bromine or iodine.
This reaction can be carried out in the usual manner. If a reactive ester of the formula IV or V is used, the reaction is preferably carried out in the pre-sence of a basic condensation agent and/or with an excess o~ amine of the formula IV. Examples of suitable basic condensation agents are alkali metal hydroxides, such as sodium hydroxide or potassium hydroxide~ alkali metal ;
carbonates, such as potassium carbonate, and alkali metal ;~
alcoholates, such as alkali metal lower alkanolates, for example sodium methylate, po-tassium ethylate or potassium . ~ , .. .
ter-tiary butylate. ~ -;
Furthermore it is possible, in a compound of the formula I, wherein Rl and R2 have the above meanings and which possess~a removable radical~on the amino group and/or on the hydroxyl group, to spllt off this radical or these radicals. ~-Such radicals which can be spli-t off are in particu-lar radicals which can be split off by solvolysis or by reduotion. ~
Examples of radloals which can be split off by ;reduction are a-arylalkyl radicals, such as benzyl radi- ~-cals,~ and ~-aralkoxycarbonyl radicals, such as benzyloxy-carbonyl rsdic~1-, whloh can~be s 1lt off in the usua1 . .
~ 4~L~9~
manner by hydrogenol~sis, especially by catalytically activated hydrogen, such as by hydrogen in the presence of a hydrogenation catalyst, for example platinum, palladium or Raney nickel. Further radicals which can be split off by hydrogenolysis are, for example, 2-halogenoalkoxy-carbonyl radicals~ such as the 2,2,2-trichloroethoxy~ - -carbonyl radical or the 2-iodoethoxy-carbonyl or Z,2,2-tribromoethoxy-carbonyl radical, which can be split off in ... ~ .. .. .
the customary manner9 especially by metallic reduction (so-called nascent hydrogen). Nascent hydrogen can be ;
obtained by the action of metal or metal alloys, such as amalgams, on agents which provide hydrogen, such as weak carboxylic acids, alcohols or water, and in particular zinc or zinc alloys together with ethanol or dilute aqueous acetic acid can be used. The hydrogenolysis of 2-halogeno-alkoxycarbonyl radicals can furthermore be effec-ted by chromium-(II) compounds, such as chromium-(II) chloride or chromium-(II) acetate. A radical which can be split off by reduction can also be an arylsulphonyl group,~such as the toluenesulphonyl group, which can be : :... .
split off in the customary manner by reduction with nascent hydrogen, for example by means of an alkali metal, : ~ .
such as lithium or sodium, in liquid ammonia, and can in ~; particular be split off from a N a-tom. :
Divalent radicals which can be split of~ by reduc- -tion~and which are substituents of the hydroxyl group and the~amlno group are, ~or example, optionally substitu-ted ;~
methylene radicals9~such as arylmethylene radicals, such -~04~ ~9~ ~
as optionally substituted benzylidene radicals, possikle substituents on the phenyl nucleus being, ~or example, halogen, such as chlorine, lower alkyl such as m~thyl, or lower alkoxy, such as methoxy. Thus, arylmethylene is in particular benzylidene. The splitting off can be effected in the customary manner, for example by catalytic ally activated hydrogen, such as by hydrogen in the pre-sence of a hydrogenation catalyst, for example platinum9 palladium or Raney nickel.
A further possible procedure is to reduce a com-pound corresponding to the formula I, wherein the nitrogen is doubly bonded to one of its substituents, or wherein a C atom bonded to the nitrogen carries a hydroxyl group.
Thus, for example, a possible procedure is -to :
. ,:. . . .
reduce a Schiff's base of the formula VI or VII
., - .
- ~ ~1 ~ O-CH2CHOHCH~-N=R2 (VI) `
~: : ~ - . ' ,". :; ., .
~ 1 ~ 0-CH2CHOECH=~ R2 (VII) ~ ~
. . -: .
or a ring tautomer corresponding to the ~ormula VI, of the ~ ~
.,; : , ~ormula VIII - -~
--- . , .
R - ~ ~CU2~ 2 (VIII) wherein Rl and R2 have the~above meaning and~R2H is ;~
:: : : : ` ' ', : ., : ` ' ~ : `: : . ' .: : "
~(~4~9~9~ `:
identical to R2.
mis reduc-tion can be effec-ted in the customary manner, for example by means of a di-light me-tal hydride, such as an alkali metal borohydride or alkali metal aluminium-hydride, for example lithium aluminium hydride, by means of a hydride, such as diborane~ or by means of hydrogen in the presence of a hydrogenation catalyst, for example platinum~ palladium or nickel, such as Raney nickel.
Care must be taken in carrying out the reduction that ~other reducible groups are not attacked.
In resulting compounds it is possible, within the ;
definition of the end products, to modify, introduce or split off substituents in the usual manner; alternatively, resulting compounds can be converted into other end pro- `~
ducts in the customary manner.
Thus it is possible to split off the protective ~`
groups in resulting compounds which carry protective groups in the sugar residue Rl. For example it is pos- ~ ~
sible, in resulting compounds in which one or more hydroxyl `
groups in the sugar residue are protected by an optionally `
substituted benzyl radical or in which two adjacen-t hyd--..... : , roxyl groups in the sugar residue Rl are together pro-tected .. . ;
by an optionally substituted benzylidene radical, to split off these radicals in the usual manner. Optionally ; . . .
substituted benzyl is, for~example, halogenobenzyl, such ~-as~chlorobenzyl,~lower alkylbenzyl, such as methylbenzyl ~;
or lower alkoxybenzyl, such as ~ethoxybenzyl, and in parti- ;
cul~r unsubstitu-ted benzyl. Optionally substituted ~
` ~ :
~:
~ , .
, ~ 4 ~ ~9 ~ :
benæylidene is, for example, halogenobenzylidene, such as chlorobenzylidene, lower alkylbenzylidene, such as methyl- ~
benzylidene, or lo-.le.r alkox~benzylidene such as methoxy- -benzylidene, and especially unsubstituted benzylldene.
m e splitting off can for example be effected by reduction, for example by treatment with catalytically activated hydrogen, such as hydrogen in -the presence of a hydro-genation catalyst, ~or example platinum, palladium or Raney nickel, yielding corresponding compounds with free : `
hydroxyl groups in the sugar residue Rl. :~
In resulting compounds in which one or more hydroxyl groups in the sugar residue Rl are protected by acyl, the acyl radicals can be split off in the customary ; .
manner, for example by hydrolysis or by alcoholysiæ, .~.`
preferably in the presence of a m.ild basic agent, such as -. ..
an alkali metal bicarbonate, for example sodium bicar~
bonate, giving corresponding compounds with free hydroxyl ~:
groups in the sugar residue R~
The reac-tions mentioned can op-tionally be carried i :
out simultaneously or successively and in optional sequence.
; me reactions mentioned are carried out in the : `~
usual manner in the presence or absence of : ~diluents, condensation agents and/or cataly-tic agents~ at ; .
: : lowered, ordinary or elevated temperature and if approp~
riate:in a closed vessel~
Depending on -the process conditions and starting aubstances, the end products are obta~ned in the free form or in the form o~ their acid addition salts, ~hich is also ~, . . . ..
.
encompassed by ~he inven-tion. Thus, for example, ~`
basic, neutral or mixed salts and where relevant also hemihydrates, monohydrates, sesquihydrates or poly-hydrates thereof7 can be obtained. The acid addition sal-ts o~ the new compounds can be converted into the free compo~md in a manner which is in itself known, for example by means of basic agents, such as alkalis or ion exchangers.
On -the other hand, the resulting ~ree bases can form salts with organic or inorganic acids. Acids used for the preparation of acid addition salts are in particular those which are suitable for forming therapeutically usable salts. ~ -As examples of such acids there may be mentioned, hydrogen halide acids, sulphuric acids, phosphoric acids, nitric `~ ~ ;
acid and aliphatic, alicyclic, aromatic or heterocyclic carboxylic acids or sulphonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid or pyruvic acid, fumaric acid, benzoic acid, anthranilic acid, p-hydroxybenzoic acid~
salicylic acid or embonic acid, methanesulphonic acid, ethanesulphonic acid, hydroxyethanesulphonic acid or ethylenesulphonic acid, halogenobenæenesulphonic acids, toluenesulphonic acid~ cyclohexylaminesulphonic acid or sulphanilic acid.
; These~or other salts of the new compounds such as, for example7 the picrates~ can also serve for the puri fication of ~he resul-ting ~ree bases by converting the ;
~ree~bases into salts, and isolating these and again i , ~ ~ .:. , .
:
: : . , , l - 13 - ; ~
~: ~ : ,.
3L~)4~
liberating the bases from the salts. Because of the close relationships between the new compounds in the free form and in the form of their salts, the free compounds are, in the preceding and following text, where appropriate also to be understood to include the corresponding salts, with regard to general sense and intended use.
m e invention also relates to those embodiments of .
the process according to which a compound obtainable as an intermediate product at any stage of -the process is used as ~he starting product and the missing process steps are carried ou-t, or the process is stopped at any sta~e, or in which a starting substance is formed under the reaction .
conditions or in which a reactant is presen-t in the form of its salts, if appropriate.
For e~ample, a possible procedure is to react an -aldehyde o~ the formula IX
~ ~ O-CH2CHO~-CHO (IX) -~
,.
with an amine H2N-R2 in the presence of a reducing agent, -- Rl and R2 having the above meaning. mis gives a compound of the formula VII as an intermediate product, which is then reduced further in accordance with the inventionO
However, another possible procedure is, for example, to` react an amine of the formula X ~
R~- ~ o-oH2cHoHc~I2-~I2 (X) ~: - . ~ . . .. .
~0~49:~
with a ketone O=R2 in the presence of a reducing agent, such as one of those mentioned above9 R2H being equivalent to R2 and Rl and ~2 having the above meaning. This gives a compound of the formula VI or VIII as an intermediate product which is then reduced further in accordance with the invention. In this case it is also possible to form i the amine X in situ, for example from one of its Schiff's bases with an optionally substituted benzaldehyde, which base is converted in situ, in particular by means of catalytic hydrogenation, into the amine X, which then --reacts further in accordance with the invention.
The new compounds can, depending on the choice of the starting substances and procedures, be in -the form of optieal antipodes or racemates or, where -they contain at least two asymmetrical carbon atoms, also in the form of isomer mixtures.
Resulting isomer mixtures ean be separated into the two stereoisomeric (diastereomeric) pure racemates ln a known manner on the basis of the physico-ehemical differences o~ the cons-tituen-ts, for example by chromato- i graphy and/or fractional crys-talllsation. i~
Resulting racemates can be resolved in-to the diastereomers according to known methods, for example by recrystallisation from an op-tically ac-tive solvent, with i ~ ....................................................................... .
the~aid of micro-organlsms or by reaction with an optically -;
aotive acid which forms sal-ts with the racemic compound and separation o~ the salts obtained in this manner, ~or example on the basis of thelr dlfferent solubillties, and ~ ; ;~
~. ..
;. : ., .. . .
, ~,.: , ~4~4~
the antipodes can be liberated from the diastereomers by ~ -treatment with suitable agen-ts. Par-ticularly cus-tomary optically ac-tive aGids are, for example, the D- and L- ~ -forms of tartaric acid, di-o-toluyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid or quinic acidO
Advantageously, the more active of the two antipodes is isolated.
Preferably, the starting substances used for carrying out the reactions according to the invention are -those which lead to the groups of end products which were particularly mentioned initially and especially to the end ~ -products which have been particularly described or singled out.
m e starting substances are known or can, i~ they `
are new, be obtainecl according to methods which are in -themselves known. Compounds IV can be prepared in the usual manner from a phenol II by reaction with a reactive ;~
derivative o~ a propanol HOCH2-CHXl-CH2Zl, such as, for example, with epichlorohydrin. Compounds I with removable ;
radicals on the amino group and/or hydroxyl group can be -:~ : ~ ..... : :
manufactured analogously to the compounds IV, as can compounds VI-X.
The new compounds can be used as medicines, for ~ ;`
example in the ~orm of pharmaceutical preparations in ~`
which they or their salts are present as a m1xture with a~pharmaceu-tical,~ organic or inorgan1c9 solid or Iiquid excip1ent~wh1ch~is su1table ~or,~ for example, enteral or-parenteral administration~ Suitable substances for 3~4~L491 ~ :
forming the excipient are those which do not react wi-th ;
the new compounds such as, for example~ water, gelatine, lactose, starch, magnesium s-teara-te, talc7 vegetable oils, benzyl alcohols, polyalkylene glycols or o-ther known medicinal excipients. The pharmaceutical preparations can for example be in the form of tablets7 dragees, capsules or suppositories or in a liquid form as solu-tions -(for example as an elixir or syrup), suspensions or emulsions. m ey are optionally sterilised and/or contain auxiliaries, such as preservati~es, stabilisers, wetting agents or emulsifiers, salts for regulating the osmotic pressure or buffers. The preparations, which can also be used in veterinary medicine, are obtained according to customary me-thods. The daily dose for a warm-blooded animal o~ about 75 kg body weigh-t is about 10-100 mg, preferably about 20-40 mg.
me examples which follow explain the invention wlthout however restricting it. ;
Example 1 -i6.4 g (0.05 mol) of 4-(2,3-epoxy-propoxy?-phenyl~
~-D-glucopyranoside and 11.8 g (0.20 mol) of isopropyl-amine are dissolved in 250 ml of methanoI and heated for
5 hours under reflux. The mixture is then completely evaporated under a waterpump vacuum. The oily residue is . ~ .
dissolved in ethanol and 8.95 g (0.05 mol) of N-cyclohexyl-sulphamic acld, dlssolved in isopropanol, are addedO m e reactlon product which precipitates in a crystall~ne form is filtered o~f whilst excluding moisture. After :~ , . ~ , ~ 17 - ~
~ . -,, . :
~4~
recrystallisa-tion ~rom ethanol-isopropanol, l-[p~ D t ' ' ' glucopyranosidyloxy)-phenoxy~-2-hydroxy-3-isopropylamino-propane-N-cyclohexyl sulphamate of melting point 70 110C
is ob-tained,[~]D - -28.8 in methanol.
m e starting material can be obtained as follows:
27.2 g (0.1 mol) of hydroquinone-~-D-gluco-pyranoside and 250 ml of epichlorohydrin are dissolved in 1 litre of e-thanol9 6.9 g (0.05 mol) of potassi~m carbonate are added and the mixture is heated ~or 6 hours under re~lux. m e precipitate which separates out is filtered off. m e ~iltrate is evaporated in a wa-terpump vacuum. m e residue is dissolved in hot ethanol and the :. . .. .
solu-tion is ~iltered. The filtrate is cooled and e-ther is added until the mixture begins to turn cloudy. me ~ .,.
reac-tion product which hereupon precipitates as crystals is ~iltered off and washed with ether. 4-(2,3-Epoxy~
propoxy)-phenyl-~-D-glucopyranoside, melting point 154~156C, [a32 - -52.4 in methanol, is thus obtained.
Exam~le 2 Analogously to -the description in Example 1, 4-(2,3-epoxy-propoxy)-phenyl-2,3,4,6-tetra-0-acetyl-~ D-glucopyranoside with isopropylamine gives l-[p-(2,3,4,6-tetra-~0-acetyl-~-D-glucopyranosidyloxy)-phenoxyJ-2- ~-.. ..
hydroxy-3 isopropylamino-propane.
AnaIogously~to the description in Example l, 4-(2,3-epoxy-propoxy)-ph~nyl-2,4-0-isopropylidene-~-D- ` -glucopyranoslde wi~h isopropylamine gives l-[p-(2,4-0-- I8 - ~ -isopropylidene ~.-D-glucopyranosidyloxy)-phenoxy]-2- :
hydroxy-3-isopropylamino-propane J
Analogously to the description in Example 1, 4-(2~3-epoxy-propoxy)-phenyl-2,4-0-benzylidene-~~D- .
glucopy.ranoside with isopropylamine gives 1-[p~(2,4-0- ..
benzylidene-~-D-glucopyr~nosidyloxy)-phenoxy~-2-hydroxy- -, .
3-isopropylamino-propane.
. Example 5 . Tablets containlng ,~0 mg of active subs-tance and .~
having the following composition are prepared in -the `
usual manner~
~ , . ~ :, . . . .
....
l-~p-(~-D~Glucopyranosidyloxy)-phenoxy]- .~;.
2-hydroxy-3-isopropylamino-propane 20 mg .. :
Wheat starch 60 mg .
Lactose 50 mg . ...
.Colloldal silica 5 mg . .-Talc 9 mg Magnesium stearate 145 mg ;. ~ -:.:. - .
Preparation :
.( . m e l-[p-(~-D~glucopyranosidyloxy)-phenoxy~-2-hydroxy-~-isopropylamino-propane is mixed with a part of the~wh~at~starch, with lactose and with colloidal sil.ica and~the mixture is forced through a sieve. : A fur~her : part of the whea-k staroh is worked in-to a paste with a ~`~
.5-fold quantity of water on~a waterbath and the powder : .
9:1.
mixture is kneaded with this paste until a slightly plastic mass has been produced. `i-m e plastic mass is forced through a sieve of approxO 3 mm mesh width and dried, and the resul-ting dry granules are again forced through a sieve. Thereafter, the residual wheat starch, talc and magnesium stearate ;.
are mixed in and the mixture is pressed to give tablets weighing 145 mg and having a breaking groove.
.
. .
- . ~ , i, . .
.... .
; ... . .
. ,. ~. . ;, ! .
~ , .' ' ., ' , ,.
. . ' " .
~: ".' '.
' . ' " " "
,' .. '`' : " ' ' ",. ', ' ~ ~ ' "' ' '. ~.' ' i ~,, . ' , :' ,' . .
. . .
.: ,,' '' ' .
~ 20 ~
dissolved in ethanol and 8.95 g (0.05 mol) of N-cyclohexyl-sulphamic acld, dlssolved in isopropanol, are addedO m e reactlon product which precipitates in a crystall~ne form is filtered o~f whilst excluding moisture. After :~ , . ~ , ~ 17 - ~
~ . -,, . :
~4~
recrystallisa-tion ~rom ethanol-isopropanol, l-[p~ D t ' ' ' glucopyranosidyloxy)-phenoxy~-2-hydroxy-3-isopropylamino-propane-N-cyclohexyl sulphamate of melting point 70 110C
is ob-tained,[~]D - -28.8 in methanol.
m e starting material can be obtained as follows:
27.2 g (0.1 mol) of hydroquinone-~-D-gluco-pyranoside and 250 ml of epichlorohydrin are dissolved in 1 litre of e-thanol9 6.9 g (0.05 mol) of potassi~m carbonate are added and the mixture is heated ~or 6 hours under re~lux. m e precipitate which separates out is filtered off. m e ~iltrate is evaporated in a wa-terpump vacuum. m e residue is dissolved in hot ethanol and the :. . .. .
solu-tion is ~iltered. The filtrate is cooled and e-ther is added until the mixture begins to turn cloudy. me ~ .,.
reac-tion product which hereupon precipitates as crystals is ~iltered off and washed with ether. 4-(2,3-Epoxy~
propoxy)-phenyl-~-D-glucopyranoside, melting point 154~156C, [a32 - -52.4 in methanol, is thus obtained.
Exam~le 2 Analogously to -the description in Example 1, 4-(2,3-epoxy-propoxy)-phenyl-2,3,4,6-tetra-0-acetyl-~ D-glucopyranoside with isopropylamine gives l-[p-(2,3,4,6-tetra-~0-acetyl-~-D-glucopyranosidyloxy)-phenoxyJ-2- ~-.. ..
hydroxy-3 isopropylamino-propane.
AnaIogously~to the description in Example l, 4-(2,3-epoxy-propoxy)-ph~nyl-2,4-0-isopropylidene-~-D- ` -glucopyranoslde wi~h isopropylamine gives l-[p-(2,4-0-- I8 - ~ -isopropylidene ~.-D-glucopyranosidyloxy)-phenoxy]-2- :
hydroxy-3-isopropylamino-propane J
Analogously to the description in Example 1, 4-(2~3-epoxy-propoxy)-phenyl-2,4-0-benzylidene-~~D- .
glucopy.ranoside with isopropylamine gives 1-[p~(2,4-0- ..
benzylidene-~-D-glucopyr~nosidyloxy)-phenoxy~-2-hydroxy- -, .
3-isopropylamino-propane.
. Example 5 . Tablets containlng ,~0 mg of active subs-tance and .~
having the following composition are prepared in -the `
usual manner~
~ , . ~ :, . . . .
....
l-~p-(~-D~Glucopyranosidyloxy)-phenoxy]- .~;.
2-hydroxy-3-isopropylamino-propane 20 mg .. :
Wheat starch 60 mg .
Lactose 50 mg . ...
.Colloldal silica 5 mg . .-Talc 9 mg Magnesium stearate 145 mg ;. ~ -:.:. - .
Preparation :
.( . m e l-[p-(~-D~glucopyranosidyloxy)-phenoxy~-2-hydroxy-~-isopropylamino-propane is mixed with a part of the~wh~at~starch, with lactose and with colloidal sil.ica and~the mixture is forced through a sieve. : A fur~her : part of the whea-k staroh is worked in-to a paste with a ~`~
.5-fold quantity of water on~a waterbath and the powder : .
9:1.
mixture is kneaded with this paste until a slightly plastic mass has been produced. `i-m e plastic mass is forced through a sieve of approxO 3 mm mesh width and dried, and the resul-ting dry granules are again forced through a sieve. Thereafter, the residual wheat starch, talc and magnesium stearate ;.
are mixed in and the mixture is pressed to give tablets weighing 145 mg and having a breaking groove.
.
. .
- . ~ , i, . .
.... .
; ... . .
. ,. ~. . ;, ! .
~ , .' ' ., ' , ,.
. . ' " .
~: ".' '.
' . ' " " "
,' .. '`' : " ' ' ",. ', ' ~ ~ ' "' ' '. ~.' ' i ~,, . ' , :' ,' . .
. . .
.: ,,' '' ' .
~ 20 ~
Claims (16)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. Process for the manufacture of 1-phenoxy-2-hydroxy-3-amino-propanes of the formula I
(I) wherein R1 is a 1-glucopyranosidyl residue which can contain protective groups and R2 is isopropyl, tert.-butyl or .alpha.-methyl-phenethyl or 1-methyl-3-phenyl-propyl which are optionally substituted in the phenyl part by one hydroxyl group or by one alkoxy group having up to 7 carbon atoms, characterized in that a) a phenol of the formula II
(II) wherein R1 has the above meaning, is reacted with a compound of the formula III
(III) wherein R2 has the above meaning, Z is reactive esterified hydroxyl and X1 is hydroxyl or Z and X1 together are epoxy, or Z and the hydrogen of the amino group together are a direct bond, or b) a compound of the formula IV
(IV) wherein R1 has the above meaning is reacted with a compound of the formula V
Z2 - R2 (V) wherein R2 has the above meaning, one of the radicals Z1 and Z2 is amino and the other is reactive esterified hydroxyl and X1 is hydroxyl, or Z1 together with XI are epoxy and Z2 is amino, or c) in a compound of the formula I except that the compound carries a radical which can be split off on the amino group and/or on the hydroxyl group , this radical or these radicals is or are split off, d) a compound corresponding to the formula 1, wherein the nitro-gen is doubly bonded to one of is substituents, or wherein a C atom bonded to the nitrogen carries a hydroxyl group, is reduced or e) a compound of formula I in which R1 contains one or more protective groups is subjected to solvolysis or hydrogenolysis to remove the protective group or groups, and if desired, resulting racemate mixtures are separated into the pure racemates and/or resulting racemates are separated into the optical antipodes and/or resulting salts are converted into other pharmaceutically acceptable salts or into the free compounds or resulting free compounds are converted into their pharmaceutically acceptable salts.
(I) wherein R1 is a 1-glucopyranosidyl residue which can contain protective groups and R2 is isopropyl, tert.-butyl or .alpha.-methyl-phenethyl or 1-methyl-3-phenyl-propyl which are optionally substituted in the phenyl part by one hydroxyl group or by one alkoxy group having up to 7 carbon atoms, characterized in that a) a phenol of the formula II
(II) wherein R1 has the above meaning, is reacted with a compound of the formula III
(III) wherein R2 has the above meaning, Z is reactive esterified hydroxyl and X1 is hydroxyl or Z and X1 together are epoxy, or Z and the hydrogen of the amino group together are a direct bond, or b) a compound of the formula IV
(IV) wherein R1 has the above meaning is reacted with a compound of the formula V
Z2 - R2 (V) wherein R2 has the above meaning, one of the radicals Z1 and Z2 is amino and the other is reactive esterified hydroxyl and X1 is hydroxyl, or Z1 together with XI are epoxy and Z2 is amino, or c) in a compound of the formula I except that the compound carries a radical which can be split off on the amino group and/or on the hydroxyl group , this radical or these radicals is or are split off, d) a compound corresponding to the formula 1, wherein the nitro-gen is doubly bonded to one of is substituents, or wherein a C atom bonded to the nitrogen carries a hydroxyl group, is reduced or e) a compound of formula I in which R1 contains one or more protective groups is subjected to solvolysis or hydrogenolysis to remove the protective group or groups, and if desired, resulting racemate mixtures are separated into the pure racemates and/or resulting racemates are separated into the optical antipodes and/or resulting salts are converted into other pharmaceutically acceptable salts or into the free compounds or resulting free compounds are converted into their pharmaceutically acceptable salts.
2. Process according to Claim 1a, characterized in that reactive esterified hydroxyl is a halogen or sulphonyloxy.
3. Process according to Claim 1b, characterized in that reactive esterified hydroxyl is a halogen or sulphonyloxy.
4. Process according to Claim 1c, characterized in that radicals which can be split off are radicals which can be split off by solvolysis or reduction.
5. Process according to Claim 4, characterized in that a monova-lent radical which can be split off by reduction is .alpha.-arylalkyl, .alpha.-aralkoxy-carbonyl, 2-halogeno-alkoxycarbonyl or arylsulphonyl.
6. Process according to Claim 4, characterized in that a divalent radical which can be split off by reduction is optionally substituted methy-lene.
7. Process according to Claim 6, characterized in that optionally substituted methylene is arylmethylene.
8. Process according to Claim 1d, characterized in that reduction is carried out with a di-light metal hydride, a hydride or hydrogen in the presence of a catalyst.
9. Process according to Claim 1, characterized in that a reactant is used in the form of its salts.
10. Process according to Claim 1, characterized in that in result-ing compounds with protective groups in the residue R1, the protective groups are split off.
11. Process according to Claim 1b, wherein R1 is 0-lower alkanoy-lated, or 0,0-ylideneylated 1-glucopyranosidyl.
12. Process according to Claim 11, wherein R1 is 0-acetyl-1-gluco-pyranosidyl, or 2,4-0-benzylidene-1-glucopyranosidyl.
13. Process according to Claim 12 wherein R1 is 2,3,4,6-tetra-0-acetyl-1-glucopyranosidyl.
14. Process according to Claim 1b, wherein R2 is isopropyl or tert.-butyl.
15. Process according to Claim 1b, characterized in that 1-[p-(.beta.-D-glucopyranosidyloxy)-phenoxy]-2-hydroxy-3-isopropylamino-propane is prepared by reaction of 4-(2,3-epoxy-propoxy)-phenyl-.beta.-D-glucopyranoside with iso-propylamine.
16. 1-Phenoxy-2-hydroxy-3-amino-propanes of the formula I
(I) wherein R1 is a 1-glucopyranosidyl residue and R2 is isopropyl, tert.-butyl or .alpha.-methyl-phenethyl or 1-methyl-3-phenyl-propyl which are optionally sub-stituted in the phenyl part by one hydroxyl group or by one alkoxy group hav-ing up to 7 carbon atoms, whenever prepared by the process claimed in claim 1 or any process which is an obvious chemical equivalent thereof.
(I) wherein R1 is a 1-glucopyranosidyl residue and R2 is isopropyl, tert.-butyl or .alpha.-methyl-phenethyl or 1-methyl-3-phenyl-propyl which are optionally sub-stituted in the phenyl part by one hydroxyl group or by one alkoxy group hav-ing up to 7 carbon atoms, whenever prepared by the process claimed in claim 1 or any process which is an obvious chemical equivalent thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1873172A CH573443A5 (en) | 1972-12-22 | 1972-12-22 | Amino-propanes - useful for heart muscle deficiency treatment 1-phenoxy-2-hydroxy-3-amino-propanes |
| CH1502273 | 1973-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1041491A true CA1041491A (en) | 1978-10-31 |
Family
ID=25715592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA187,308A Expired CA1041491A (en) | 1972-12-22 | 1973-12-04 | Process for the manufacture of new amines |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS4988833A (en) |
| AR (2) | AR203835A1 (en) |
| CA (1) | CA1041491A (en) |
| DD (1) | DD110260A5 (en) |
| DE (1) | DE2361355A1 (en) |
| ES (1) | ES421739A1 (en) |
| FR (1) | FR2211228B1 (en) |
| GB (1) | GB1447558A (en) |
| IE (1) | IE38607B1 (en) |
| IL (1) | IL43742A (en) |
| LU (1) | LU69046A1 (en) |
| NL (1) | NL7316948A (en) |
| NO (1) | NO139168C (en) |
| SE (1) | SE411673B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA956632A (en) * | 1969-05-16 | 1974-10-22 | Yoshitomi Pharmaceutical Industries | Phenoxy-aminopropanol derivatives |
-
1973
- 1973-11-26 SE SE7315965A patent/SE411673B/en unknown
- 1973-12-03 IL IL43742A patent/IL43742A/en unknown
- 1973-12-04 IE IE2191/73A patent/IE38607B1/en unknown
- 1973-12-04 CA CA187,308A patent/CA1041491A/en not_active Expired
- 1973-12-07 NO NO4690/73A patent/NO139168C/en unknown
- 1973-12-10 DE DE2361355A patent/DE2361355A1/en not_active Withdrawn
- 1973-12-11 NL NL7316948A patent/NL7316948A/xx not_active Application Discontinuation
- 1973-12-12 GB GB5758373A patent/GB1447558A/en not_active Expired
- 1973-12-17 FR FR7344999A patent/FR2211228B1/fr not_active Expired
- 1973-12-20 LU LU69046A patent/LU69046A1/xx unknown
- 1973-12-20 DD DD175546A patent/DD110260A5/xx unknown
- 1973-12-21 AR AR251664A patent/AR203835A1/en active
- 1973-12-22 JP JP48143007A patent/JPS4988833A/ja active Pending
- 1973-12-22 ES ES421739A patent/ES421739A1/en not_active Expired
-
1974
- 1974-01-01 AR AR256894A patent/AR206799A1/en active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2211228A1 (en) | 1974-07-19 |
| IL43742A (en) | 1977-01-31 |
| DD110260A5 (en) | 1974-12-12 |
| IL43742A0 (en) | 1974-03-14 |
| AU6381773A (en) | 1975-06-26 |
| LU69046A1 (en) | 1975-08-20 |
| NO139168C (en) | 1979-01-17 |
| AR206799A1 (en) | 1976-08-23 |
| ES421739A1 (en) | 1976-09-16 |
| AR203835A1 (en) | 1975-10-31 |
| IE38607B1 (en) | 1978-04-26 |
| IE38607L (en) | 1974-06-22 |
| FR2211228B1 (en) | 1976-12-03 |
| JPS4988833A (en) | 1974-08-24 |
| NO139168B (en) | 1978-10-09 |
| NL7316948A (en) | 1974-06-25 |
| SE411673B (en) | 1980-01-28 |
| GB1447558A (en) | 1976-08-25 |
| DE2361355A1 (en) | 1974-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3340266A (en) | (3-amino-2-hydroxypropoxy)-benzoheterocyclic derivatives | |
| US7087768B2 (en) | Fumagillol derivatives and preparing method thereof | |
| US4034009A (en) | 4-Ureido-2-acyl phenoxypropanolamine | |
| WO1992012981A1 (en) | Substituted phenyl-1,3 dioxoloquinoline derivatives and their use as antitumor agents | |
| KR940002822B1 (en) | 6-substituted furinyl piperazine derivatives | |
| JPS61246184A (en) | Dianhydrohexite derivative, manufacture and use as medicine | |
| AU750666B2 (en) | Pyranones, method for the production and use thereof | |
| CA1157474A (en) | Aromatic aminoethanol compounds, process for production thereof, and utilization thereof | |
| US3663570A (en) | Coumarin derivatives | |
| US3755413A (en) | 1-cyanophenoxy-2-hydroxy-3-(cycloalkyl-amino)-propanes | |
| FI69835B (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA 3-NDOLYL-TERTIAERBUTYLAMINOPROPANOLDERIVAT | |
| CA1041491A (en) | Process for the manufacture of new amines | |
| IL25425A (en) | Process for the manufacture of 4,1-benzothiazepin-2-one derivatives and novel 4,1-benzothiazepin-2-one derivatives | |
| JPS61501854A (en) | Novel dopamine agonist | |
| EP0259087B1 (en) | Prodrugs of antihypercholesterolemic compounds | |
| US3018222A (en) | Central stimulant and appetite depressant composition | |
| US3629266A (en) | (phenyl piperidino alkyl)3 4-dihydrocarbostyrils | |
| US3896119A (en) | Xanthines substituted in the 8-position | |
| US3984436A (en) | Pyrrolyl compounds and processes for their manufacture | |
| CZ263692A3 (en) | Thiadiazinones, process of their preparation and pharmaceutical compositions based thereon | |
| US3853899A (en) | 7-alkyl-2,2-dimethyl-4-(1-aralkyl-1,2,3,4-tetrahydro-4-pyridyl)-chroman-5-ols and derivatives thereof | |
| CA1053705A (en) | Process for the manufacture of a new 1-phenoxy-3-isopropylamino-2-propanol | |
| CA1197847A (en) | N-substituted polyglycidyl urazole compounds, processes for their production and pharmaceutical preparations | |
| GB1591723A (en) | 1-amino-2-hydroxy-3-heterocyclyloxy-propanes | |
| JPH03503900A (en) | Heterocyclic sulfonyl nitromethane, its manufacturing process and pharmaceutical formulations |